David Flowers

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 9

Top Topics

Recombinant Human

Top Venues

Cancer research

CPT: pharmacometrics & systems pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Sarah A Head, Carter Johnson, Saheli Sarkar, Andrew Matteson, Diana H Marcantonio, Fei Hua, John M Burke, Joshua F Apgar, David Flowers
Comparison of dose selection based on target engagement versus inhibition of receptor-ligand interaction for checkpoint inhibitors. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Sarah A Head, Carter Johnson, Saheli Sarkar, Andrew Matteson, Diana H Marcantonio, Fei Hua, John M Burke, Joshua F Apgar, David Flowers
Comparison of dose selection based on target engagement versus inhibition of receptor-ligand interaction for checkpoint inhibitors. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Hui Yuwen, Huajing Wang, Tengteng Li, Yijing Ren, Yun-Kai Zhang, Peng Chen, Ao Sun, Gang Bian, Bohua Li, David Flowers, Marc Presler, Kalyanasundaram Subramanian, Jia Xue, Jingjing Wang, Kevin Lynch, Jay Mei, Xiaowen He, Bo Shan, Bing Hou
ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation. Cancer research 84 (10) (2024)
Hui Yuwen, Huajing Wang, Tengteng Li, Yijing Ren, Yun-Kai Zhang, Peng Chen, Ao Sun, Gang Bian, Bohua Li, David Flowers, Marc Presler, Kalyanasundaram Subramanian, Jia Xue, Jingjing Wang, Kevin Lynch, Jay Mei, Xiaowen He, Bo Shan, Bing Hou
ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation. Cancer research 84 (10) (2024)
Sarah A Head, Carter Johnson, Saheli Sarkar, Andrew Matteson, Diana H Marcantonio, Fei Hua, John M Burke, Joshua F Apgar, David Flowers
Comparison of dose selection based on target engagement versus inhibition of receptor-ligand interaction for checkpoint inhibitors. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Hui Yuwen, Huajing Wang, Tengteng Li, Yijing Ren, Yun-Kai Zhang, Peng Chen, Ao Sun, Gang Bian, Bohua Li, David Flowers, Marc Presler, Kalyanasundaram Subramanian, Jia Xue, Jingjing Wang, Kevin Lynch, Jay Mei, Xiaowen He, Bo Shan, Bing Hou
ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation. Cancer research 84 (10) (2024)
Hui Yuwen, Huajing Wang, Tengteng Li, Yijing Ren, Yun-Kai Zhang, Peng Chen, Ao Sun, Gang Bian, Bohua Li, David Flowers, Marc Presler, Kalyanasundaram Subramanian, Jia Xue, Jingjing Wang, Kevin Lynch, Jay Mei, Xiaowen He, Bo Shan, Bing Hou
ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation. Cancer research 84 (10) (2024)
Hui Yuwen, Huajing Wang, Tengteng Li, Yijing Ren, Yun-Kai Zhang, Peng Chen, Ao Sun, Gang Bian, Bohua Li, David Flowers, Marc Presler, Kalyanasundaram Subramanian, Jia Xue, Jingjing Wang, Kevin Lynch, Jay Mei, Xiaowen He, Bo Shan, Bing Hou
ATG-101 is a tetravalent PD-L1×4-1BB bispecific antibody that stimulates anti-tumor immunity through PD-L1 blockade and PD-L1-directed 4-1BB activation. Cancer research (2024)
Sarah A Head, Carter Johnson, Saheli Sarkar, Andrew Matteson, Diana H Marcantonio, Fei Hua, John M Burke, Joshua F Apgar, David Flowers
Comparison of dose selection based on target engagement versus inhibition of receptor-ligand interaction for checkpoint inhibitors. CPT: pharmacometrics & systems pharmacology (2024)